Close Menu

NEW YORK (GenomeWeb) – Menarini-Silicon Biosystems said today that it has signed an agreement to purchase all the assets and relevant business related to the Cellsearch circulating tumor cell (CTC) system from Janssen Diagnostics for an undisclosed amount.

Cellsearch is used to help manage patients with metastatic breast, prostate, and colorectal cancers. It is the only US Food and Drug Administration-cleared CTC test, and has been approved by the China FDA for use in monitoring breast cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.